证券代码：000950 证券简称：重药控股 公告编号：2025-076 重药控股股份有限公司 一、会议召开情况 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.本次股东会没有出现否决议案的情形。 2.本次股东会不涉及变更前次股东会决议。 （一）现场会议召开时间：2025 年 10 月 22 日（星期三）14:30。 （七）公司于 2025 年 9 月 30 日、2025 年 10 月 18 日分别在巨潮资讯网 www.cninfo.com.cn 及《中国证券报》、《证券时报》、《证券日报》、《上海 证券报》上刊登了《关于召开 2025 年第四次临时股东会的通知》、《关于召开 2025 年第四次临时股东会的提示性公告》。 网络投票时间：2025 年 10 月 22 日。其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 10 月 22 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 10 月 22 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于重药控股股份有限公司 2025 年第四次临时股东会的 律师见证法律意见书 1、2025 年 9 月 29 日，公司召开第九届董事会第十八次会议，审议通过了 《关于召开 2025 年第四次临时股东会的议案》，决定由公司董事会召集，并于 2025 年 10 月 22 日召开本次股东会。 致：重药控股股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受重药控股股份有限公 司（以下简称"公司"）的委托，指派律师列席公司于 2025 年 10 月 22 日召开的 公司 2025 年第四次临时股东会（以下简称"本次股东会"）。根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》和《深圳证券交易所股票上市规则》等现行有 关法律、法规、规范性文件以及《重药控股股份有限公司公司章程》（以下简称 "《公司章程》"）的规定，本所律师对公 ...

从资金流向上来看，当日医药商业板块主力资金净流出9842.13万元，游资资金净流出5145.31万元，散户 资金净流入1.5亿元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 601607 | 上海医药 | | 3193.68万 | 11.80% | -1918.99万 | -7.09% | -1274.70万 | -4.71% | | 301584 建发致新 | | | 1863.79万 | 2.54% | 209.26万 | 0.29% | -2073.05万 | -2.83% | | 000705 浙江震元 | | | 797.60万 | 4.74% | 1045.76万 | 6.21% | -- 1843.36万 | -10.95% | | 002462 | 嘉事堂 | | 454.40万 | 6.43% | -496.57万 | -7.03% | 42. ...

证券之星消息，10月20日医疗耗材供应链SPD板块较上一交易日上涨0.41%，建发致新领涨。当日上证指 数报收于3863.89，上涨0.63%。深证成指报收于12813.21，上涨0.98%。医疗耗材供应链SPD板块个股涨 跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301584 | 建发致新 | 29.30 | 4.46% | 18.64万 | 5.34 Z | | 301126 | 达嘉维康 | 11.75 | 3.07% | 5.35万 | 6221.88万 | | 605186 | 健摩信息 | 19.55 | 2.68% | 1.72万 | 3343.23万 | | 603122 | 合富中国 | 6.40 | 1.91% | 4.41万 | 2806.45万 | | 300288 | 朗玛信息 | 13.68 | 1.48% | 3.64万 | 4968.35万 | | 603716 | 塞力医疗 | 26.11 | 1.48% | 19.46万 | 5.03亿 | ...

证券代码：000950 证券简称：重药控股 公告编号：2025-075 重药控股股份有限公司 关于召开 2025 年第四次临时股东会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 重药控股股份有限公司（以下简称"公司"）于 2025 年 9 月 30 日在《中国 证券报》、《证券时报》、《证券日报》、《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）上刊登了《关于召开 2025 年第四次临时股东会的通 知》（公告编号：2025-070）。本次股东会将采用现场投票与网络投票相结合的 方式进行，现再次将本次股东会的有关事项提示如下： 一、召开会议的基本情况 1.股东会届次：2025 年第四次临时股东会 2.股东会召集人：重药控股股份有限公司董事会 3.会议召开的合法性和合规性：公司第九届董事会第十八次会议审议通过了 《关于召开 2025 年第四次临时股东会的议案》，本次股东会会议召开符合有关 法律、行政法规、部门规章、规范性文件和公司章程的有关规定。 4.会议召开的日期和时间： （1）现场会议召开时间：2025 年 10 月 ...

Market Overview - The pharmaceutical commercial sector increased by 0.17% on October 14, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.19, up 1.35% with a trading volume of 48,200 shares and a transaction value of 127 million [1] - China Pharmaceutical (600056) closed at 11.26, up 1.26% with a trading volume of 278,600 shares and a transaction value of 313 million [1] - Dazhenlin (603233) closed at 16.81, up 1.14% with a trading volume of 75,200 shares [1] - Other notable performers include Jianfa Zhixin (301584) up 1.01% and Renmin Tongtai (600829) also up 1.01% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 129 million from institutional investors, while retail investors saw a net inflow of 209 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Saily Medical (603716) had a net inflow of 27.9 million from institutional investors, but a net outflow of 21.2 million from speculative funds [3] - Jianfa Zhixin (301584) saw a net inflow of 11.02 million from institutional investors, with a net outflow of 9.78 million from speculative funds [3] - Yifeng Pharmacy (603939) had a net inflow of 9.47 million from institutional investors, while retail investors experienced a net outflow of 13.37 million [3]

Group 1: Innovation in Pharmaceuticals - The State Council has introduced regulations to standardize clinical research and application of biomedical technologies, promoting innovation and ensuring medical quality and safety [1] - The innovative pharmaceutical industry is experiencing positive fundamentals, with overseas licensing amounts exceeding $66.8 billion by mid-2025, and 31% of innovative drugs introduced by international pharmaceutical companies originating from China [1] Group 2: Infrastructure Development - Seven departments, including the Ministry of Industry and Information Technology, have released a plan to enhance new information infrastructure, focusing on the integration of "5G + industrial internet" and the development of computing power infrastructure [2] - The plan aims to promote the resourceization and assetization of industrial data, and to integrate artificial intelligence technologies with service-oriented manufacturing [2] Group 3: Financial Standards - The China Securities Regulatory Commission has published three financial industry standards related to securities exchanges and asset securitization, effective immediately [3] Group 4: Housing and Urban Development - The Ministry of Housing and Urban-Rural Development is deepening reforms in the housing and real estate sectors during the 14th Five-Year Plan, aiming to establish a new model for real estate development and improve the housing supply system [4] Group 5: Healthcare Pricing Regulation - The National Healthcare Security Administration has initiated a special rectification of "dual pricing" practices in designated retail pharmacies, emphasizing the need for fair pricing for insured patients [5][6] Group 6: Cloud Computing Standards - The Ministry of Industry and Information Technology and the National Standardization Administration have issued guidelines for the construction of a comprehensive cloud computing standardization system, aiming to establish over 30 new national and industry standards by 2027 [7] Group 7: Company News - Nengke Technology plans to raise up to 1 billion yuan for the development of its AI training platform [8] - Various companies reported significant year-on-year profit increases, with notable growth from Dao Shi Technology (408.27%) and Dongyangguang (171.08% - 199.88%) [8]

Investment Rating - The report indicates a positive investment outlook for the innovative pharmaceutical sector, suggesting a focus on companies with sustained high growth in performance [3][4][11]. Core Insights - The innovative pharmaceutical industry is expected to continue its high revenue growth trend, with specific attention on companies in the medical devices, CXO, and upstream sectors [3][4]. - The report highlights the performance forecasts for 22 pharmaceutical companies, with several expected to achieve significant profit growth in Q3 2025 [3][4]. - The report emphasizes the importance of monitoring companies that consistently maintain high growth rates, such as 恒瑞医药 (Hengrui Medicine), 迈瑞医疗 (Mindray), and others [3][4][11]. Performance Forecasts - As of October 11, 2025, two pharmaceutical companies have released their Q3 2025 performance forecasts, with 重药控股 (Zhongyao Holdings) expecting a profit growth rate between 39.89% and 117.47%, and ST 诺泰 (ST Nuotai) expecting a growth rate between 5.62% and 13.74% [4]. - The report predicts that five companies will achieve profit growth rates of 40% or more, including 以岭药业 (Yiling Pharmaceutical) and 福瑞股份 (Furui Co.) [3][4]. - Revenue forecasts for 33 pharmaceutical companies indicate that seven companies are expected to achieve revenue growth rates of 40% or more, including 三生国健 (3SBio) and 艾迪药业 (Eddie Pharmaceuticals) [3][4]. Company-Specific Insights - The report provides detailed profit and revenue forecasts for various companies, indicating significant expected growth for companies like 以岭药业 (Yiling Pharmaceutical) with a projected profit increase of 1150% year-on-year [6][9]. - Specific revenue growth rates are forecasted for companies such as 恒瑞医药 (Hengrui Medicine), which is expected to achieve a revenue increase of 12% to 17% [10][11]. - The report includes a valuation table for key companies, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for the coming years [11].

Investment Rating - The industry investment rating is "Overweight," indicating that the industry is expected to outperform the overall market [18]. Core Insights - The report emphasizes the sustained high growth of innovative drugs and suggests focusing on companies with consistently high performance in the innovative drug sector, as well as those in the medical devices, CXO, and upstream segments that are showing significant improvement [3][4]. Performance Forecast - As of October 11, 2025, two pharmaceutical companies have released performance forecasts for Q3 2025, with Heavy Drug Holdings expecting a profit growth rate between 40% and 117%, and ST Nuotai expecting a growth rate between 6% and 14% [4]. - For Q3 2025, the report predicts the following net profit growth rates for 22 pharmaceutical companies: - 5 companies with growth rates of 40% and above: Yiling Pharmaceutical, Furuide, Huakang Clean, Haitai New Light, and Beida Pharmaceutical - 3 companies with growth rates between 20% and 35%: Heng Rui Pharmaceutical, Jianyou Pharmaceutical, and Zuoli Pharmaceutical - 7 companies with growth rates between 10% and 20%: Wo Wu Biological, Jingxin Pharmaceutical, Enhua Pharmaceutical, Xinmai Medical, Kaiyin Technology, Huaxia Eye Hospital, and Qianyuan Pharmaceutical - 6 companies with growth rates between 0% and 10%: Aier Eye Hospital, Kangchen Pharmaceutical, Renfu Pharmaceutical, Weier Pharmaceutical, Jiuzhitang, and Guangyuyuan - 1 company is expected to turn a profit: New Mileage [3][4][6]. Revenue Forecast - The report forecasts revenue growth for 33 pharmaceutical companies in Q3 2025 as follows: - 7 companies with growth rates of 40% and above: San Sheng Guo Jian, Aidi Pharmaceutical, Xinmai Medical, Zejing Pharmaceutical-U, Huakang Clean, Dize Pharmaceutical-U, and Haitai New Light - 9 companies with growth rates between 20% and 40%: Nuo Cheng Jian Hua-U, Bai Ji Shen Zhou-U, Wei Xin Biological, Jun Shi Biological-U, Furuide, Kang Huo Nuo, Meng Ke Pharmaceutical-U, Ke Xing Pharmaceutical, and Qianyuan Pharmaceutical - 10 companies with growth rates between 10% and 20%: Olin Biological, Beida Pharmaceutical, Xinlitai, Wo Wu Biological, Guangyuyuan, Heng Rui Pharmaceutical, Kaili Medical, Kangchen Pharmaceutical, Kaiyin Technology, and Wu Ming Kang De - 3 companies with growth rates between 5% and 10%: Enhua Pharmaceutical, Mai Rui Medical, and Aier Eye Hospital - 4 companies with growth rates between 0% and 5%: Changchun High-tech, Runda Medical, Weier Pharmaceutical, and Yiling Pharmaceutical [3][7][9]. Key Companies to Watch - The report suggests focusing on companies that are expected to maintain high growth in Q3 2025, including Heng Rui Pharmaceutical, Changchun High-tech, Kelong Pharmaceutical, Enhua Pharmaceutical, Mai Rui Medical, Furuide, Xiangsheng Medical, Huakang Clean, Wu Ming Kang De, Kanglong Huacheng, Kailai Ying, Pruisi, and Hanbang Technology [3][4].

智通财经APP讯，重药控股(000950.SZ)发布2025年前三季度业绩预告，预计前三季度归属于上市公司股 东的净利润3.58亿元至4亿元，同比增长22.51%—36.88%。公司药品、器械、中药、专业药房、新兴业 务等业务持续发展，不断完善网络布局，营业收入实现稳步增长;通过精细化管理，提升经营管理效 率，实现降本增效。 ...